AMRX
Amneal Pharmaceuticals, Inc.Company Information
- Company Name
- Amneal Pharmaceuticals, Inc.
- CIK
- CIK0001723128
- Category
- Large accelerated filer
- Ticker: Exchange
- AMRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AMRX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-08-13
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 1,231,515
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 161,537,721
- Shares outstanding
- 319,200,000
- Ownership
- 50.61%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -2.93%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | 170 | 851 | 895 | 78 | 53 | 754 | 776 | -22 | 101 | 669 | 614 | 16 | ||||||
| Related Party | 170 | 851 | 895 | 78 | 53 | 754 | 776 | -22 | 101 | 669 | 614 | 16 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 128 | 198 | 282 | 201 | 72 | 59 | 111 | 74 | 44 | 47 | 92 | 87 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 9 | 4 | 29 | 35 | 10 | 7 | 8 | 4 | 6 | 5 | 8 | 9 | ||||||
| Inventory Net | 678 | 642 | 606 | 615 | 609 | 601 | 612 | 596 | 576 | 571 | 581 | 576 | ||||||
| Prepaid Expense And Other Assets Current | 112 | 103 | 98 | 102 | 85 | 89 | 81 | 82 | 82 | 87 | 83 | 91 | ||||||
| Assets Current | 1,947 | 1,798 | 1,911 | 1,838 | 1,585 | 1,510 | 1,588 | 1,513 | 1,485 | 1,380 | 1,378 | 1,456 | ||||||
| Property Plant And Equipment Net | 457 | 445 | 443 | 435 | 440 | 427 | 425 | 431 | 425 | 440 | 448 | 452 | ||||||
| Goodwill | 593 | 594 | 595 | 596 | 597 | 597 | 597 | 598 | 599 | 599 | 599 | 599 | ||||||
| Intangible Assets Net Excluding Goodwill | 588 | 535 | 563 | 588 | 650 | 689 | 732 | 780 | 820 | 859 | 890 | 983 | ||||||
| Operating Lease Right Of Use Asset | - | - | 54 | - | - | - | 42 | - | - | - | 43 | - | ||||||
| Other Assets Noncurrent | 81 | 55 | 58 | 39 | 45 | 45 | 60 | 36 | 77 | 74 | 56 | 89 | ||||||
| Assets | 3,776 | 3,540 | 3,678 | 3,600 | 3,423 | 3,365 | 3,501 | 3,461 | 3,510 | 3,456 | 3,473 | 3,687 | ||||||
Liabilities Current | ||||||||||||||||||
| Litigation Reserve Current | 18 | 11 | 43 | 41 | 42 | 44 | 32 | 30 | 31 | 30 | 77 | 77 | ||||||
| Lines Of Credit Current | 100 | - | 0 | 0 | 290 | 290 | 100 | 140 | 179 | 179 | 179 | 76 | ||||||
| Long Term Debt Current | 6 | 6 | 7 | 7 | 31 | 32 | 224 | 225 | 225 | 34 | 34 | 31 | ||||||
| Liabilities Current | 883 | 728 | 882 | 862 | 1,107 | 1,076 | 1,130 | 1,095 | 1,114 | 834 | 847 | 761 | ||||||
| Long Term Debt Noncurrent | 2,564 | 2,566 | 2,565 | 2,567 | 2,146 | 2,154 | 2,162 | 2,170 | 2,178 | 2,378 | 2,386 | 2,542 | ||||||
| Other Notes Payable | - | - | - | - | - | - | - | 0 | 0 | 42 | 41 | 41 | ||||||
| Litigation Reserve Noncurrent | 71 | 70 | 72 | 74 | 74 | 73 | 85 | 85 | 85 | 85 | 0 | - | ||||||
| Liabilities Noncurrent | 2,776 | 2,772 | 2,791 | 2,780 | 2,362 | 2,349 | 2,416 | 2,399 | 2,400 | 2,639 | 2,565 | 2,735 | ||||||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | 84 | 86 | 77 | 68 | 66 | 73 | 65 | 60 | 53 | 47 | 41 | 37 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 546 | 536 | 572 | 563 | 555 | 546 | 560 | 553 | 546 | 539 | 539 | 715 | ||||||
| Retained Earnings Accumulated Deficit | -415 | -473 | -535 | -570 | -572 | -595 | -607 | -576 | -576 | -582 | -490 | -392 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -101 | -112 | -111 | -106 | -97 | -86 | -66 | -74 | -30 | -24 | -32 | 4 | ||||||
| Stockholders Equity | 33 | -45 | -71 | -109 | -112 | -132 | -109 | -93 | -57 | -64 | 20 | 154 | ||||||
| Minority Interest | 0 | -1 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -177 | ||||||
| Liabilities And Stockholders Equity | 3,776 | 3,540 | 3,678 | 3,600 | 3,423 | 3,365 | 3,501 | 3,461 | 3,510 | 3,456 | 3,473 | 3,687 | ||||||
| Common Class A | 0 | 0 | 0 | -314 | 1 | 313 | 0 | 0 | 1 | 309 | 0 | 0 | ||||||
| Common Class B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAmneal Pharmaceuticals, Inc. (AMRX) — SEC Financial Statements & Analysis
Amneal Pharmaceuticals, Inc. (AMRX) is a pharmaceutical preparations company. Amneal Pharmaceuticals, Inc. trades on Nasdaq as: AMRX. Amneal Pharmaceuticals, Inc. (AMRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Amneal Pharmaceuticals, Inc. carries a market cap of $5.53B, a P/E ratio of 25.66x, a P/B ratio of 167.31x, a P/S ratio of 1.77x, an enterprise value of $8.07B, and an EV/EBITDA multiple of 17.77x. On profitability, it posts a gross margin of 39.32%, an operating margin of 14.56%, a net margin of 6.91%, a Return on Equity (ROE) of -544.46%, a Return on Assets (ROA) of 5.98%, and a Return on Invested Capital (ROIC) of 18.23%. Per share, it reports EPS of $0.67, diluted EPS of $0.66, free cash flow per share of $0.40, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 9.28% year-over-year, net income growth of 642.71% year-over-year, and EPS growth of 630.00% year-over-year. On the balance sheet, it maintains a current ratio of 2.20x, a quick ratio of 1.31x, working capital of $1.06B, a debt-to-equity ratio of 110.81x, a debt ratio of 0.97, an interest coverage ratio of 2.00x, free cash flow of $127.83M (TTM), and net debt of $2.54B. Figures sourced from SEC EDGAR.
- Market Cap
- $5.53B
- P/E TTM
- 25.66x
- EPS TTM
- $0.67
- P/B TTM
- 167.31x
- ROE TTM
- -544.46%
- ROA TTM
- 5.98%
- Debt To Equity
- 110.81x
- Free Cash Flow TTM
- $127.83M
- Net Revenue TTM Growth 1Y
- 9.28%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Amneal Pharmaceuticals, Inc. in?
Amneal Pharmaceuticals, Inc. (AMRX) operates in the Pharmaceutical Preparations industry.
What exchange does AMRX trade on?
Amneal Pharmaceuticals, Inc. (AMRX) trades on the Nasdaq.
When was Amneal Pharmaceuticals, Inc. (AMRX)'s most recent SEC filing?
Amneal Pharmaceuticals, Inc. (AMRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is AMRX's market cap?
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $5.53B as of 2026-06-30.
What is AMRX's P/E ratio?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month P/E ratio is 25.66x as of 2026-06-30.
What is AMRX's EPS (earnings per share)?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month EPS is $0.67 as of 2026-06-30.
What is AMRX's ROE (return on equity)?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month Return on Equity (ROE) is -544.46% as of 2026-06-30.
What is AMRX's ROA (return on assets)?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month Return on Assets (ROA) is 5.98% as of 2026-06-30.
What is AMRX's ROIC (return on invested capital)?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month Return on Invested Capital (ROIC) is 18.23% as of 2026-06-30.
What is AMRX's EV/EBITDA?
Amneal Pharmaceuticals, Inc. (AMRX)'s trailing twelve month EV/EBITDA is 17.77x as of 2026-06-30.